Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Michael

Showing results (191-200 of 216) with videos related to

Pageof 22
Sort By:
Journal of Cancer|April 30, 2025
Integration of multi-omics and single-cell transcriptome reveals mitochondrial outer membrane protein-2 (MTX-2) as a prognostic biomarker and characterizes ubiquinone metabolism in lung adenocarcinomaSachin Kumar, Chung-Che Wu, Fitria Sari Wulandari, et al.
British Journal of Cancer|March 6, 2024
Early onset pancreatic cancer-exploring contemporary treatment and outcomes using real-world dataShehara Mendis, Lara Lipton, Yat Hang To, et al.
European Journal of Clinical Pharmacology|September 4, 2021
Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolitesZheng Liu, Jennifer H Martin, Winston Liauw, et al.
BMC Public Health|August 26, 2025
Exploring the association between Cultural and Linguistic Diversity (CALD) on treatment and outcomes in pancreatic cancer: an analysis of PURPLE real-world registry data from an Australian populationEmma Sanderson, Belinda Lee, Nadia Ayres, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2023
A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) StudyLavinia Tan, Ben Tran, Jeanne Tie, et al.
JAMA Oncology|July 3, 2025
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical TrialBo Gao, Matteo S Carlino, Michael Michael, et al.
Heliyon|January 15, 2025
A non-randomised open-label exploratory 'window of opportunity' study of TG02 treatment in patients with locally advanced primary and recurrent <i>RAS</i> mutant colorectal cancerSara Roth, Kasmira Claire Wilson, Robert George Ramsay, et al.
Neuroendocrinology|September 1, 2022
Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide TherapyMinmin Li, David L Chan, Gonzalo Tapia Rico, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 27, 2009
The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serumJennifer A Westwood, William K Murray, Melanie Trivett, et al.
The New England Journal of Medicine|September 16, 2024
Preoperative Chemoradiotherapy for Resectable Gastric CancerTrevor Leong, B Mark Smithers, Michael Michael, et al.
Pageof 22

Showing results (191-200 of 216) with videos related to

Sort By:
Pageof 22
Journal of Cancer|April 30, 2025
Integration of multi-omics and single-cell transcriptome reveals mitochondrial outer membrane protein-2 (MTX-2) as a prognostic biomarker and characterizes ubiquinone metabolism in lung adenocarcinomaSachin Kumar, Chung-Che Wu, Fitria Sari Wulandari, et al.
British Journal of Cancer|March 6, 2024
Early onset pancreatic cancer-exploring contemporary treatment and outcomes using real-world dataShehara Mendis, Lara Lipton, Yat Hang To, et al.
European Journal of Clinical Pharmacology|September 4, 2021
Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolitesZheng Liu, Jennifer H Martin, Winston Liauw, et al.
BMC Public Health|August 26, 2025
Exploring the association between Cultural and Linguistic Diversity (CALD) on treatment and outcomes in pancreatic cancer: an analysis of PURPLE real-world registry data from an Australian populationEmma Sanderson, Belinda Lee, Nadia Ayres, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2023
A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) StudyLavinia Tan, Ben Tran, Jeanne Tie, et al.
JAMA Oncology|July 3, 2025
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical TrialBo Gao, Matteo S Carlino, Michael Michael, et al.
Heliyon|January 15, 2025
A non-randomised open-label exploratory 'window of opportunity' study of TG02 treatment in patients with locally advanced primary and recurrent <i>RAS</i> mutant colorectal cancerSara Roth, Kasmira Claire Wilson, Robert George Ramsay, et al.
Neuroendocrinology|September 1, 2022
Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide TherapyMinmin Li, David L Chan, Gonzalo Tapia Rico, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 27, 2009
The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serumJennifer A Westwood, William K Murray, Melanie Trivett, et al.
The New England Journal of Medicine|September 16, 2024
Preoperative Chemoradiotherapy for Resectable Gastric CancerTrevor Leong, B Mark Smithers, Michael Michael, et al.
Pageof 22